ESTRO 35 2016 ______________________________________________________________________________________________________ have been to determine an MR sequence capable of visualising the tumour and finding a suitable esophageal applicator that can be visualised on the MR images.
Material and Methods:
A total of six patients were included in this study. Each patient was scanned with one of two T2weighted sequences, inversion recovery fast spin echo (IR FSE) or fast recovery fast spin echo (FRFSE) . To reduce the motion artefacts in the images, the scanning was only triggered when the diaphragm was at the end-exhale position. The imaging was performed on a 3.0 T MR (GE Healthcare). Dose planning on the obtained MR images was performed using two different methods 1) dose was prescribed at 10 mm from the applicator's centre, which is the method currently used at Skåne University Hospital for treatment based on 2D images 2) dose planning was performed by manual optimisation, i.e. the dwell times were manually adjusted until adequate tumour coverage was reached. To our knowledge, an MR-safe esophageal applicator could not be found at the time of this study. Instead a modified duodenal tube was used. Different contrast agents were studied with the purpose to render the tube's visibility on the MR images.
Results:
The esophageal tumour was successfully visualised and delineated on T2-weighted images with the FRFSE sequences, whereas the tumour in the MR images from the IR FSE sequences was difficult to visualise due to poor image quality. Furthermore, improved dose coverage to the tumour was observed when the dose planning was manually optimised to the tumour volume, where V100% to the tumour was increased from 70% to 95% and D90% was increased by 34%. Moreover, the esophageal applicator (duodenal tube) was filled with a saline solution, which was successfully visualised on the MR images.
Conclusion:
Brachytherapy dose planning for esophageal cancer with MR imaging enhances tumour visibility and the ability to optimise the dose to the tumour volume and organs at risk.
PO-0967
Current practice in quality assurance of the Papillon50 contact X-ray brachytherapy system in the UK L. Humbert-Vidan Purpose or Objective; Papillon50 contact brachytherapy has been used for early rectal cancer treatment in the UK since 1993. Currently there are four centres treating and a few more are in the process of implementation. The National Institute for Health and Care Excellence has issued guidance on safety and efficacy from a clinical perspective. However, there is currently no guidance on quality assurance (QA) testing. This review assessed any significant differences in machine QA practice between the current UK Papillon50 users. This is the first step towards standardising QA tests, tolerances and procedures in order to ensure that the accuracy of this technique is maintained at a high level across the UK.
Material and Methods:
Each centre provided in-depth information regarding their QA programme. Details on machine-specific design characteristics were also taken into account. An inter-departmental comparison was made with regards to the QA tests performed, the frequency of each test, the accepted accuracy of the results with respect to the set baselines, the setup for each test and the equipment used.
Results: Significant differences were seen between centres in the QA tests in terms of types of test, frequency and acceptable accuracy. A tolerance variation of 10% versus 2% in the beam quality check and a difference of 2 mm versus 0.5 mm in the radiation field size check were observed. The manufacturer provides a calibration jig with which all four centres carry out radiation output measurements. However, each centre uses its own HVL jig design. There are significant design differences between these jigs with respect to the source-to-detector distance (SDD), the narrow beam geometry achieved and the backscatter conditions. All centres use the 1996 IPEMB CoP for the determination of absorbed dose for x-rays below 300 kV generating potential and its Addendum (2005) as a reference for the determination of the radiation output. However, the reference conditions stated in the CoP were generally not met due to the inherent design of the calibration jig used.
Conclusion: Significant differences exist between centres in the level of accuracy and extent of the QA programme. The very-low energy and short SDD in the Papillon50 system result in a very rapid dose fall-off. Differences in the design of the HVL jig may play an important role in the definition of the beam quality in such conditions. An extension of the CoP Addendum may be needed to include the achievable Papillon50 measurement conditions. This review highlights the need to carry out an independent audit in order to assess whether the inter-departmental variations observed could result in differences in the treatment received by patients.
PO-0968
Development of a fluorescent screen based QA system for dose verification of afterloading HDR unit T.L. Chiu 
